China Shineway Pharmaceutical Group Reports 16.3% Drop in Nine-Month Turnover

Reuters

2025/11/07

<a href="https://laohu8.com/S/CSWYY">China Shineway</a> Pharmaceutical Group Reports 16.3% Drop in Nine-Month Turnover

China Shineway Pharmaceutical Group Limited announced that its turnover for the nine months ended 30 September 2025 was RMB 2,415 million, representing a decrease of 16.3% compared to the same period in 2024. Turnover of injection products declined by 23.6% to RMB 786 million, soft capsule products decreased by 13.7% to RMB 337 million, granule products fell by 14.5% to RMB 391 million, TCM formula granule products dropped by 11.8% to RMB 726 million, and products in other forms decreased by 6.1% to RMB 175 million. Injection products, soft capsule products, granule products, and TCM formula granule products accounted for approximately 32.5%, 14.0%, 16.2%, and 30.1% of total turnover, respectively, during the period. The results are based on management accounts that have not been reviewed by auditors.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. China Shineway Pharmaceutical Group Ltd. published the original content used to generate this news brief on November 07, 2025, and is solely responsible for the information contained therein.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2581907024"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2581907024\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2581907024?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-07 12:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581907024","market":"us","top_or_hot":-1,"title":"China Shineway Pharmaceutical Group Reports 16.3% Drop in Nine-Month Turnover","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/CSWYY\">China Shineway</a> Pharmaceutical Group Reports 16.3% Drop in Nine-Month Turnover\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        China Shineway Pharmaceutical Group Limited announced that its turnover for the nine months ended 30 September 2025 was RMB 2,415 million, representing a decrease of 16.3% compared to the same period in 2024. Turnover of injection products declined by 23.6% to RMB 786 million, soft capsule products decreased by 13.7% to RMB 337 million, granule products fell by 14.5% to RMB 391 million, TCM formula granule products dropped by 11.8% to RMB 726 million, and products in other forms decreased by 6.1% to RMB 175 million. Injection products, soft capsule products, granule products, and TCM formula granule products accounted for approximately 32.5%, 14.0%, 16.2%, and 30.1% of total turnover, respectively, during the period. The results are based on management accounts that have not been reviewed by auditors.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/CSWYF\">China Shineway Pharmaceutical Group Ltd.</a> published the original content used to generate this news brief on November 07, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>China Shineway Pharmaceutical Group Reports 16.3% Drop in Nine-Month Turnover</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChina Shineway Pharmaceutical Group Reports 16.3% Drop in Nine-Month Turnover\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-07 12:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/CSWYY\">China Shineway</a> Pharmaceutical Group Reports 16.3% Drop in Nine-Month Turnover\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        China Shineway Pharmaceutical Group Limited announced that its turnover for the nine months ended 30 September 2025 was RMB 2,415 million, representing a decrease of 16.3% compared to the same period in 2024. Turnover of injection products declined by 23.6% to RMB 786 million, soft capsule products decreased by 13.7% to RMB 337 million, granule products fell by 14.5% to RMB 391 million, TCM formula granule products dropped by 11.8% to RMB 726 million, and products in other forms decreased by 6.1% to RMB 175 million. Injection products, soft capsule products, granule products, and TCM formula granule products accounted for approximately 32.5%, 14.0%, 16.2%, and 30.1% of total turnover, respectively, during the period. The results are based on management accounts that have not been reviewed by auditors.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/CSWYF\">China Shineway Pharmaceutical Group Ltd.</a> published the original content used to generate this news brief on November 07, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1606","symbol_name":"中医药概念","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nNDLbKGkyK:1","article_id":"2581907024","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581907024","pubTimestamp":1762488425,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"China Shineway Pharmaceutical Group Limited announced that its turnover for the nine months ended 30 September 2025 was RMB 2,415 million, representing a decrease of 16.3% compared to the same period in 2024. Turnover of injection products declined by 23.6% to RMB 786 million, soft capsule products decreased by 13.7% to RMB 337 million, granule products fell by 14.5% to RMB 391 million, TCM formula granule products dropped by 11.8% to RMB 726 million, and products in other forms decreased by 6.1% to RMB 175 million. Injection products, soft capsule products, granule products, and TCM formula granule products accounted for approximately 32.5%, 14.0%, 16.2%, and 30.1% of total turnover, respectively, during the period. The results are based on management accounts that have not been reviewed by auditors.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated c","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1606":"中医药概念","02877":"神威药业","BK1191":"制药"},"translate_title":"神威药业集团报告9个月营业额下降16.3%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02877":0.9},"content_text":"China Shineway Pharmaceutical Group Reports 16.3% Drop in Nine-Month Turnover\n    \n\n        China Shineway Pharmaceutical Group Limited announced that its turnover for the nine months ended 30 September 2025 was RMB 2,415 million, representing a decrease of 16.3% compared to the same period in 2024. Turnover of injection products declined by 23.6% to RMB 786 million, soft capsule products decreased by 13.7% to RMB 337 million, granule products fell by 14.5% to RMB 391 million, TCM formula granule products dropped by 11.8% to RMB 726 million, and products in other forms decreased by 6.1% to RMB 175 million. Injection products, soft capsule products, granule products, and TCM formula granule products accounted for approximately 32.5%, 14.0%, 16.2%, and 30.1% of total turnover, respectively, during the period. The results are based on management accounts that have not been reviewed by auditors.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. China Shineway Pharmaceutical Group Ltd. published the original content used to generate this news brief on November 07, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}